KELYA:NASDAQKelly Services, Inc. Analysis
Data as of 2026-04-12 - not real-time
$8.71
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Kelly Services trades around $8.71, just above its 20‑day SMA (8.69) but well below the 50‑day (9.37) and 200‑day (10.96) averages, indicating short‑term resilience but a longer‑term bearish bias. The RSI sits at 44, suggesting neutral momentum, while the MACD line is modestly above its signal, producing a small positive histogram that hints at limited upside momentum. Volatility is elevated at 24.6% over the past 30 days and the stock has experienced a historic drawdown of nearly 45%, underscoring substantial price swings. Despite a trailing PE of zero and a forward PE of 5.2—far below the industry average of 30.9—the company posted a -5.98% profit margin and a -11.9% revenue decline, reflecting ongoing earnings pressure. However, free cash flow remains positive at $170.6 M and the dividend yield of 3.44% is supported by a modest payout ratio of 26%, indicating current cash generation can sustain the payout.
Recent material news includes the appointment of Joel Leege as President of the Science, Engineering & Technology segment, signaling a strategic focus on higher‑margin talent solutions, and an insider purchase of 100 shares at $14.77, which, despite being well above market price, conveys confidence from management. The DCF‑derived fair value of $63.8 suggests a potential upside of over 90%, though such a gap may be tempered by execution risk. Overall, the stock appears deeply undervalued on a book‑value basis (price‑to‑book 0.30) and dividend yield, but faces significant execution and market‑timing challenges.
Recent material news includes the appointment of Joel Leege as President of the Science, Engineering & Technology segment, signaling a strategic focus on higher‑margin talent solutions, and an insider purchase of 100 shares at $14.77, which, despite being well above market price, conveys confidence from management. The DCF‑derived fair value of $63.8 suggests a potential upside of over 90%, though such a gap may be tempered by execution risk. Overall, the stock appears deeply undervalued on a book‑value basis (price‑to‑book 0.30) and dividend yield, but faces significant execution and market‑timing challenges.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering just above short‑term support (8.29) with decreasing volume
- Neutral momentum (RSI 44) and modest bullish MACD histogram
- High short‑term volatility and bearish longer‑term moving averages
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward EPS estimate of $1.67 and low forward PE of 5.2
- Strong free cash flow and sustainable dividend yield
- Strategic leadership appointment and insider buying indicating confidence
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value implying >90% upside relative to current price
- Deep discount to book value (price‑to‑book 0.30) and low valuation multiples
- Potential sector recovery and continued cash‑flow generation despite current losses
Key Metrics & Analysis
Financial Health
Revenue Growth-11.90%
Profit Margin-5.98%
P/E Ratio5.2
ROE-22.98%
ROA1.40%
Debt/Equity16.29
P/B Ratio0.3
Op. Cash Flow$122.6M
Free Cash Flow$170.6M
Industry P/E30.9
Technical Analysis
TrendBearish
RSI43.9
Support$8.29
Resistance$9.20
MA 20$8.69
MA 50$9.37
MA 200$10.96
MACDBullish
VolumeDecreasing
Fear & Greed Index87.09
Valuation
Fair Value$63.83
Target Price$16.67
Upside/Downside91.35%
GradeUndervalued
TypeValue
Dividend Yield3.44%
Risk Assessment
Beta0.91
Volatility24.59%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.